Skip to main content

Table 2 Comparison of plasma AGEs levels and plasma sRAGE levels in 52 patients with adult-onset Still’s disease (AOSD), 36 patients with systemic lupus erythematosus (SLE), and 16 healthy subjects (HC)

From: The potential role of advanced glycation end products (AGEs) and soluble receptors for AGEs (sRAGE) in the pathogenesis of adult-onset still’s disease

AGEs and sRAGE, patient groups Median (interquartile range)
AGEs levels, μg/mL  
 Active AOSD (n=30) 16.75 (12.45-24.66)**##§§§
 Inactive AOSD (n=22) 7.02 (5.43-9.01)
 Active SLE (n=25) 14.80 (10.68-21.42)**##§§
 Inactive SLE (n=11) 6.49 (4.40-11.10)
 HC (n=16) 9.80 (4.55-10.83)
sRAGE levels, pg/mL  
 Active AOSD (n=30) 632.2 (437.8-866.9)**#§§§
 Inactive AOSD (n=22) 858.9 (599.8-1222.2)§
 Active SLE (n=25) 771.6 (553.0-1069.1)*§§
 Inactive SLE (n=11) 1480.0 (892.1-1686.9)
 HC (n=16) 1051.7 (738.2-1468.3)
  1. AGEs: advanced glycation end products; sRAGE: soluble receptor for AGEs.
  2. *p<0.05, **p<0.001, versus HC; #p<0.05, ##p<0.001 versus inactive AOSD;
  3. §p<0.05, §§p<0.005, §§§p<0.001, versus inactive SLE.
  4. Mann-Whitney U test was used for between-group comparison of numerical variables.